WO1990003181A3 - Utilisation d'antagonistes de peptides dans le traitement du cancer et utilisation de l'oncogene mas et de ses produits - Google Patents

Utilisation d'antagonistes de peptides dans le traitement du cancer et utilisation de l'oncogene mas et de ses produits Download PDF

Info

Publication number
WO1990003181A3
WO1990003181A3 PCT/GB1989/001121 GB8901121W WO9003181A3 WO 1990003181 A3 WO1990003181 A3 WO 1990003181A3 GB 8901121 W GB8901121 W GB 8901121W WO 9003181 A3 WO9003181 A3 WO 9003181A3
Authority
WO
WIPO (PCT)
Prior art keywords
product
angiotensin
mas oncogene
cancer therapy
peptide antagonists
Prior art date
Application number
PCT/GB1989/001121
Other languages
English (en)
Other versions
WO1990003181A2 (fr
Inventor
Michael Robert Hanley
Michel Goedert
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of WO1990003181A2 publication Critical patent/WO1990003181A2/fr
Publication of WO1990003181A3 publication Critical patent/WO1990003181A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Il a été démontré que l'oncogène mas code pour un récepteur angiotensine. On peut donc utiliser une substance qui arrête l'activité biologique de l'angiotensine dans le traitement ou la prévention de l'évolution des tumeurs ou la production d'hormones ectopiques. Parmi les substances qui conviennent à cela, on compte des antagoniste d'angiotensine, des agonistes partiels des angiotensines et des anticorps aux angiotensines. On décrit également l'utilisation du produit de l'oncogène mas dans un système d'analyse pour inhiber activité de l'angiotensine.
PCT/GB1989/001121 1988-09-24 1989-09-22 Utilisation d'antagonistes de peptides dans le traitement du cancer et utilisation de l'oncogene mas et de ses produits WO1990003181A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8822483.7 1988-09-24
GB888822483A GB8822483D0 (en) 1988-09-24 1988-09-24 Developments relating to mas oncogene

Publications (2)

Publication Number Publication Date
WO1990003181A2 WO1990003181A2 (fr) 1990-04-05
WO1990003181A3 true WO1990003181A3 (fr) 1990-05-03

Family

ID=10644185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1989/001121 WO1990003181A2 (fr) 1988-09-24 1989-09-22 Utilisation d'antagonistes de peptides dans le traitement du cancer et utilisation de l'oncogene mas et de ses produits

Country Status (3)

Country Link
AU (1) AU4324089A (fr)
GB (1) GB8822483D0 (fr)
WO (1) WO1990003181A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3968193A (en) * 1992-03-26 1993-10-21 Gensia, Inc. In vivo peptide therapy
NZ313713A (en) * 1995-08-02 2001-03-30 Univ Newcastle Ventures Ltd Benzimidazole-4-carboxamide derivatives useful as poly(ADP-ribose)polymerase or PARP enzyme inhibitors
EP1268795A2 (fr) * 2000-03-24 2003-01-02 Bayer Aktiengesellschaft Regulation du recepteur couple a la proteine g associee a l'oncogene mas humain
WO2001072840A2 (fr) * 2000-03-27 2001-10-04 Pe Corporation (Ny) Recepteurs couples aux proteines g humaines isoles de la sous-famille des proto-oncogenes mas, molecules d'acide nucleique codant les proteines rcpg humaines et leur utilisations
PT2376101E (pt) 2008-12-29 2016-02-04 Trevena Inc Efectores da beta-arrestina e composições e métodos para a sua utilização
CN104168907A (zh) 2012-01-31 2014-11-26 特维娜有限公司 β-抑制蛋白效应器及其组合物与使用方法
EP3102223A4 (fr) 2014-02-07 2017-11-29 Trevena, Inc. Formes cristallines et amorphes d'un effecteur bêta-arrestine
US9611293B2 (en) 2014-05-19 2017-04-04 Trevena, Inc. Synthesis of beta-arrestin effectors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Experientia, Vol. 36, No. 4, 1980, Birkhauser Verlag, (Basel, CH), P. SCHELLING et al.: "Effects of Angiotensin II and of an Angiotensin II Receptor on Simian Virus 40-Induced Tumor Growth in Vivo", pages 452-454, see the whole article *
Medical and Pediatric Oncology, Vol. 14, No. 1, 1986, Alan R. Liss, Inc., (New York, US), K.C. STINE et al.: "Congestive Heart Failure, Hypertension, and Hyperreninemia in Bilateral Wilms' Tumor: Successful Medical Management", pages 63-66, see Abstract; "Discussion" *

Also Published As

Publication number Publication date
WO1990003181A2 (fr) 1990-04-05
AU4324089A (en) 1990-04-18
GB8822483D0 (en) 1988-10-26

Similar Documents

Publication Publication Date Title
DE3773057D1 (de) Vorrichtung zur kontrollierten abgabe von arzneimitteln, ihre zubereitung und verwendung.
DE3586713T2 (de) Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
EP0554383A4 (fr)
CS553490A3 (en) Transdermal therapeutic system
DE3685094D1 (de) Pharmazeutisches praeparat zur kontrollierten freisetzung von wirkstoffen.
NO891351L (no) Flytende rensemiddelblanding og fremgangsmaate for fremstilling av denne.
NO307031B1 (no) Farmasøytiske produkter for legning av tumorsykdommer, og fremgangsmåte for fremstilling av disse
WO1997008318A3 (fr) Composes et procedes de traitement et de diagnostic du cancer de la prostate
AU601765B2 (en) Polypeptide useful for the alleviation, treatment and diagnosis of autoimmune diseases, especially arthritic conditions etc.,
WO1990003181A3 (fr) Utilisation d'antagonistes de peptides dans le traitement du cancer et utilisation de l'oncogene mas et de ses produits
NL190399B (nl) Ijzer-bevattend eiwitmateriaal, bereiding daarvan, en farmaceutisch preparaat voor de behandeling van sideropene anaemie.
NO902809D0 (no) Anordning og fremgangsmaate for fremstilling av syntesegass, samt anvendelse av denne.
WO2001018046A3 (fr) Sequences de tumeurs ovariennes et procedes d'utilisation correspondants
AU2792789A (en) Method and means for selection of anti-idiotype antibodies and their use for the diagnosis, monitoring, treatment and/or prevention of cancer, autoimmune or infectious disease
DE3788852T2 (de) Proteine mit Glutathion-S-Transferase-Aktivität, DNA-Sequenzen, Antikörper, Poxviren und Arzneimittel zur Prävention von Schistosomiasis.
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
IT8821743A0 (it) Materiali biologici, procedimenti per produrre materiali biologici e per usare tali materiali in terapia.
WO1990013643A3 (fr) Molecules receptrices d'hormone de glycoproteine
IE781840L (en) Detecting cancerigenic and anticancerous substances
WO1990013644A3 (fr) Domaine cytoplasmique soluble du recepteur de glycoproteine cd2 humaine
HUP9800744A2 (hu) Fas-antigén elleni antitestek
NL189958B (nl) Werkwijze en inrichting voor de vervaardiging van grondstofbriketten voor de bereiding van silicium of van siliciumcarbide of van ferrosilicium.
IT8723058A0 (it) Procedimento per la compressione di materiali granulari di formatura.
FR2611205B1 (fr) Dipeptides, procede de preparation et utilisation dans le dosage de proteases
DE3856530D1 (de) Gerät zur Behandlung von pulverförmigem, granuliertem und konglomeriertem Material mit zugehörigem Analyseverfahren

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642